NorGenoTech AS is a European biotechnology company specializing in advanced DNA damage and repair analysis for research, industry, and healthcare. The company originated from the EC-funded COMICS project, which delivered major advances in high-throughput genotoxicity testing. Today, NorGenoTech combines validated laboratory services, expert consultancy, and modern analytical platforms to support chemical safety assessment, nanosafety, environmental monitoring, and human biomonitoring, while maintaining the agility of a modern SME.

The company was founded by Professor Andrew Collins, Dr Gunnar Brunborg, Dr. Maria Dusinski, Dr Amaya Azqueta and Dr. Sergey Shaposhnikov; internationally recognized pioneers in genetic toxicology and the development of the comet assay. NorGenoTech is currently led by Dr Sergey Shaposhnikov, who heads the company’s scientific and operational strategy. Under his leadership, NorGenoTech continues to translate decades of methodological innovation into robust, regulatory-relevant services for both public and private partners.

NorGenoTech’s core expertise lies in genotoxicity and cytotoxicity testing, with particular emphasis on DNA damage, DNA repair, and the safety assessment of nano- and advanced materials in line with EC REACH and Safe and Sustainable by Design (SSbD) principles. The company offers a comprehensive portfolio of OECD-guideline assays, including high- and medium-throughput comet assays, in vivo and in vitro genotoxicity tests, and specialized DNA repair capacity measurements. These services support the development of pharmaceuticals, chemicals, biocides, cosmetics, food-related products, and emerging nanotechnologies.

In addition to service provision, NorGenoTech is actively involved in European collaborative research projects, including the EU-funded NANO2FILM project, which focuses on targeted lipid nanocarriers against drug-resistant bacterial biofilms, and the Marie Skłodowska-Curie Doctoral Network NANAQUA, addressing nanotechnology-enabled water treatment. The company also contributes to peer-reviewed scientific output, with multiple publications in 2025 (PMID: 40382189, 40219078, 40180023), reflecting its continued engagement with innovation while remaining strongly application- and impact-driven.